To assess the impact of statin therapy on liver enzyme levels (alanine aminotransferase (ALT), aspartate aminotransferase (AST)) and liver fibrosis progression in patients with both CVD and NAFLD, and to determine the potential dual benefits of statins for managing both liver and cardiovascular health. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.